Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?

Gauthier S, Zhang H, Ng KP, Pascoal TA, Rosa-Neto P.

Transl Neurodegener. 2018 May 31;7:12. doi: 10.1186/s40035-018-0117-9. eCollection 2018. Review.

2.

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.

Meyer PF, Savard M, Poirier J, Labonté A, Rosa-Neto P, Weitz TM, Town T, Breitner J; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group.

J Alzheimers Dis. 2018;63(2):577-590. doi: 10.3233/JAD-170887.

3.

Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.

Gauthier S, Ng KP, Pascoal TA, Zhang H, Rosa-Neto P.

J Alzheimers Dis. 2018 Mar 1. doi: 10.3233/JAD-179924. [Epub ahead of print]

PMID:
29504543
4.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

PMID:
29482212
5.

CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem.

Benedet AL, Yu L, Labbe A, Mathotaarachchi S, Pascoal TA, Shin M, Kang MS, Gauthier S, Rouleau GA, Poirier J, Bennett DA, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Neurol Genet. 2018 Jan 30;4(1):e216. doi: 10.1212/NXG.0000000000000216. eCollection 2018 Feb.

6.

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.

Therriault J, Ng KP, Pascoal TA, Mathotaarachchi S, Kang MS, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V, Gauthier S, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2018 Mar 13;90(11):e932-e939. doi: 10.1212/WNL.0000000000005120. Epub 2018 Feb 14.

7.

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.

Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1021-1030. doi: 10.1007/s00259-018-3933-3. Epub 2018 Feb 2.

8.

Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.

Henriques AD, Benedet AL, Camargos EF, Rosa-Neto P, Nóbrega OT.

Exp Gerontol. 2018 Jul 1;107:169-177. doi: 10.1016/j.exger.2018.01.002. Epub 2018 Jan 4. Review.

PMID:
29307736
9.

Identification of [18F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging.

Bernard-Gauthier V, Mossine AV, Mahringer A, Aliaga A, Bailey JJ, Shao X, Stauff J, Arteaga J, Sherman P, Grand'Maison M, Rochon PL, Wängler B, Wängler C, Bartenstein P, Kostikov A, Kaplan DR, Fricker G, Rosa-Neto P, Scott PJH, Schirrmacher R.

J Med Chem. 2018 Feb 22;61(4):1737-1743. doi: 10.1021/acs.jmedchem.7b01607. Epub 2018 Jan 5.

PMID:
29257860
10.

Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.

Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner J, Chakravarty MM; PREVENT-AD Research Group.

Hum Brain Mapp. 2018 Feb;39(2):971-984. doi: 10.1002/hbm.23897. Epub 2017 Nov 21.

PMID:
29164798
11.

Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.

Li X, Ba M, Ng KP, Mathotaarachchi S, Pascoal TA, Rosa-Neto P, Gauthier S.

Alzheimers Dement (Amst). 2017 Sep 5;10:12-21. doi: 10.1016/j.dadm.2017.08.001. eCollection 2018.

12.

Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.

Parent MJ, Zimmer ER, Shin M, Kang MS, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Do Carmo S, Dea D, Poirier J, Soucy JP, Gauthier S, Cuello AC, Rosa-Neto P.

J Neurosci. 2017 Dec 13;37(50):12263-12271. doi: 10.1523/JNEUROSCI.1346-17.2017. Epub 2017 Nov 2.

13.

Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.

Gauthier S, Ng KP, Pascoal TA, Mathotaarachchi S, Chung CO, Benedetti AL, Shin M, Kang MS, Li X, Ba M, Kandiah N, Rosa-Neto P.

Neurology. 2017 Oct 31;89(18):1931. doi: 10.1212/WNL.0000000000004593. No abstract available.

PMID:
29084927
14.

The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database.

Ba M, Li X, Ng KP, Pascoal TA, Mathotaarachchi S, Rosa-Neto P, Gauthier S; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (N Y). 2017 Feb 9;3(1):107-113. doi: 10.1016/j.trci.2016.12.005. eCollection 2017 Jan.

15.

Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease.

Tuwaig M, Savard M, Jutras B, Poirier J, Collins DL, Rosa-Neto P, Fontaine D, Breitner JCS; PREVENT-AD Research Group.

J Alzheimers Dis. 2017;60(4):1589-1600. doi: 10.3233/JAD-170545.

16.

Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.

Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA.

Mol Psychiatry. 2017 Nov;22(11):1531-1538. doi: 10.1038/mp.2017.183. Epub 2017 Sep 12.

PMID:
28894304
17.

Identifying incipient dementia individuals using machine learning and amyloid imaging.

Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MS, Beaudry T, Fonov VS, Gauthier S, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2017 Nov;59:80-90. doi: 10.1016/j.neurobiolaging.2017.06.027. Epub 2017 Jul 11.

18.

A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human.

Bernard-Gauthier V, Bailey JJ, Mossine AV, Lindner S, Vomacka L, Aliaga A, Shao X, Quesada CA, Sherman P, Mahringer A, Kostikov A, Grand'Maison M, Rosa-Neto P, Soucy JP, Thiel A, Kaplan DR, Fricker G, Wängler B, Bartenstein P, Schirrmacher R, Scott PJH.

J Med Chem. 2017 Aug 24;60(16):6897-6910. doi: 10.1021/acs.jmedchem.7b00396. Epub 2017 Jul 21.

PMID:
28696690
19.

Odor identification as a biomarker of preclinical AD in older adults at risk.

Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS; PREVENT-AD Research Group.

Neurology. 2017 Jul 25;89(4):327-335. doi: 10.1212/WNL.0000000000004159. Epub 2017 Jun 28.

20.

Consensus guidelines for lumbar puncture in patients with neurological diseases.

Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE.

Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007. eCollection 2017.

21.

Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease.

Dadar M, Pascoal TA, Manitsirikul S, Misquitta K, Fonov VS, Tartaglia MC, Breitner J, Rosa-Neto P, Carmichael OT, Decarli C, Collins DL.

IEEE Trans Med Imaging. 2017 Aug;36(8):1758-1768. doi: 10.1109/TMI.2017.2693978. Epub 2017 Apr 12.

PMID:
28422655
22.

Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.

Ng KP, Pascoal TA, Mathotaarachchi S, Chung CO, Benedet AL, Shin M, Kang MS, Li X, Ba M, Kandiah N, Rosa-Neto P, Gauthier S; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2017 May 9;88(19):1814-1821. doi: 10.1212/WNL.0000000000003916. Epub 2017 Apr 12.

23.

Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking.

Chamoun M, Huppé-Gourgues F, Legault I, Rosa-Neto P, Dumbrava D, Faubert J, Vaucher E.

Front Hum Neurosci. 2017 Mar 21;11:128. doi: 10.3389/fnhum.2017.00128. eCollection 2017.

24.

Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.

Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P.

Alzheimers Res Ther. 2017 Mar 31;9(1):25. doi: 10.1186/s13195-017-0253-y.

25.

[18F]FDG PET signal is driven by astroglial glutamate transport.

Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim HI, Gauthier S, Pellerin L, Hamel E, Rosa-Neto P.

Nat Neurosci. 2017 Mar;20(3):393-395. doi: 10.1038/nn.4492. Epub 2017 Jan 30.

26.

Synergistic interaction between amyloid and tau predicts the progression to dementia.

Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, Beaudry T, Kang MS, Soucy JP, Labbe A, Gauthier S, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2017 Jun;13(6):644-653. doi: 10.1016/j.jalz.2016.11.005. Epub 2016 Dec 23.

27.

A dataset of multiresolution functional brain parcellations in an elderly population with no or mild cognitive impairment.

Tam A, Dansereau C, Badhwar A, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P, Shmuel A, Breitner J, Bellec P; Alzheimer׳s Disease Neuroimaging Initiative.

Data Brief. 2016 Nov 18;9:1122-1129. eCollection 2016 Dec.

28.

Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?

Ba M, Kong M, Li X, Ng KP, Rosa-Neto P, Gauthier S.

Transl Neurodegener. 2016 Nov 16;5:20. doi: 10.1186/s40035-016-0067-z. eCollection 2016. Review.

29.

Deletion of the mu opioid receptor gene in mice reshapes the reward-aversion connectome.

Mechling AE, Arefin T, Lee HL, Bienert T, Reisert M, Ben Hamida S, Darcq E, Ehrlich A, Gaveriaux-Ruff C, Parent MJ, Rosa-Neto P, Hennig J, von Elverfeldt D, Kieffer BL, Harsan LA.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11603-11608. Epub 2016 Sep 26.

30.

Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.

DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E.

Cereb Cortex. 2016 Oct 17;26(11):4170-4179. doi: 10.1093/cercor/bhw249.

31.

Towards the PET radiotracer for p75 neurotrophin receptor: [(11)C]LM11A-24 shows biological activity in vitro, but unfavorable ex vivo and in vivo profile.

Gibon J, Kang MS, Aliaga A, Sharif B, Rosa-Neto P, Séguéla P, Barker PA, Kostikov A.

Bioorg Med Chem. 2016 Oct 1;24(19):4759-4765. doi: 10.1016/j.bmc.2016.08.020. Epub 2016 Aug 13.

PMID:
27567078
32.

Principal component of explained variance: An efficient and optimal data dimension reduction framework for association studies.

Turgeon M, Oualkacha K, Ciampi A, Miftah H, Dehghan G, Zanke BW, Benedet AL, Rosa-Neto P, Greenwood CM, Labbe A; Alzheimer’s Disease Neuroimaging Initiative.

Stat Methods Med Res. 2018 May;27(5):1331-1350. doi: 10.1177/0962280216660128. Epub 2016 Jul 26.

PMID:
27460538
33.

VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis.

Mathotaarachchi S, Wang S, Shin M, Pascoal TA, Benedet AL, Kang MS, Beaudry T, Fonov VS, Gauthier S, Labbe A, Rosa-Neto P.

Front Neuroinform. 2016 Jun 15;10:20. doi: 10.3389/fninf.2016.00020. eCollection 2016.

34.

Remodeling of Neuronal Circuits After Reach Training in Chronic Capsular Stroke.

Cho J, Kwon DH, Kim RG, Song H, Rosa-Neto P, Lee MC, Kim HI.

Neurorehabil Neural Repair. 2016 Nov;30(10):941-950. Epub 2016 May 18.

PMID:
27198184
35.

Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.

Gauthier S, Rosa-Neto P, Kass JS.

Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):615-8. doi: 10.1212/CON.0000000000000306.

36.

Imaging Alzheimer's disease pathophysiology with PET.

Schilling LP, Zimmer ER, Shin M, Leuzy A, Pascoal TA, Benedet AL, Borelli WV, Palmini A, Gauthier S, Rosa-Neto P.

Dement Neuropsychol. 2016 Apr-Jun;10(2):79-90. doi: 10.1590/S1980-5764-2016DN1002003. Review.

37.

Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.

Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung CO, Shin M, Wang S, Beaudry T, Kang MS, Soucy JP, Labbe A, Gauthier S, Rosa-Neto P.

Mol Psychiatry. 2017 Feb;22(2):306-311. doi: 10.1038/mp.2016.37. Epub 2016 Mar 29.

38.

Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.

Laforce R, Rosa-Neto P, Soucy JP, Rabinovici GD, Dubois B, Gauthier S.

Can J Neurol Sci. 2016 Jul;43(4):503-12. doi: 10.1017/cjn.2015.401. Epub 2016 Feb 26.

PMID:
26916179
39.

Common Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies.

Tam A, Dansereau C, Badhwar A, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P, Shmuel A, Wang S, Breitner J, Bellec P; Alzheimer's Disease Neuroimaging Initiative.

Front Aging Neurosci. 2015 Dec 24;7:242. doi: 10.3389/fnagi.2015.00242. eCollection 2015.

40.
41.

Sensory-parietal cortical stimulation improves motor recovery in severe capsular infarct.

Kim RG, Cho J, Ree J, Kim HS, Rosa-Neto P, Kim JM, Lee MC, Kim HI.

J Cereb Blood Flow Metab. 2016 Dec;36(12):2211-2222. Epub 2015 Nov 4.

42.

Epistasis analysis links immune cascades and cerebral amyloidosis.

Benedet AL, Labbe A, Lemay P, Zimmer ER, Pascoal TA, Leuzy A, Mathotaarachchi S, Mohades S, Shin M, Dionne-Laporte A, Beaudry T, Picard C, Gauthier S, Poirier J, Rouleau G, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

J Neuroinflammation. 2015 Dec 1;12:227. doi: 10.1186/s12974-015-0436-z.

43.

Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease.

Orban P, Madjar C, Savard M, Dansereau C, Tam A, Das S, Evans AC, Rosa-Neto P, Breitner JC, Bellec P; PREVENT-AD Research Group.

Sci Data. 2015 Oct 13;2:150043. doi: 10.1038/sdata.2015.43. eCollection 2015.

44.

Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET.

DuBois JM, Rousset OG, Rowley J, Porras-Betancourt M, Reader AJ, Labbe A, Massarweh G, Soucy JP, Rosa-Neto P, Kobayashi E.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):152-62. doi: 10.1007/s00259-015-3167-6. Epub 2015 Aug 21.

PMID:
26290423
45.

Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone.

Zimmer ER, Parent MJ, Leuzy A, Aliaga A, Aliaga A, Moquin L, Schirrmacher ES, Soucy JP, Skelin I, Gratton A, Gauthier S, Rosa-Neto P.

J Cereb Blood Flow Metab. 2015 Jul;35(7):1169-74. doi: 10.1038/jcbfm.2015.35. Epub 2015 Mar 25.

46.

In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.

Leuzy A, Zimmer ER, Dubois J, Pruessner J, Cooperman C, Soucy JP, Kostikov A, Schirmaccher E, Désautels R, Gauthier S, Rosa-Neto P.

Brain Struct Funct. 2016 Apr;221(3):1387-402. doi: 10.1007/s00429-014-0978-3. Epub 2015 Jan 18.

PMID:
25596865
47.

Developments in Tau PET Imaging.

Zimmer ER, Leuzy A, Gauthier S, Rosa-Neto P.

Can J Neurol Sci. 2014 Sep;41(5):547-53. doi: 10.1017/cjn.2014.15. Review.

PMID:
25424608
48.

Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents.

Bernard-Gauthier V, Aliaga A, Aliaga A, Boudjemeline M, Hopewell R, Kostikov A, Rosa-Neto P, Thiel A, Schirrmacher R.

ACS Chem Neurosci. 2015 Feb 18;6(2):260-76. doi: 10.1021/cn500193f. Epub 2014 Nov 10.

PMID:
25350780
49.

Deficit in sustained attention following selective cholinergic lesion of the pedunculopontine tegmental nucleus in rat, as measured with both post-mortem immunocytochemistry and in vivo PET imaging with [¹⁸F]fluoroethoxybenzovesamicol.

Cyr M, Parent MJ, Mechawar N, Rosa-Neto P, Soucy JP, Clark SD, Aghourian M, Bedard MA.

Behav Brain Res. 2015 Feb 1;278:107-14. doi: 10.1016/j.bbr.2014.09.021. Epub 2014 Sep 22.

PMID:
25257103
50.

MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.

Zimmer ER, Parent MJ, Cuello AC, Gauthier S, Rosa-Neto P.

Trends Neurosci. 2014 Nov;37(11):629-41. doi: 10.1016/j.tins.2014.07.002. Epub 2014 Aug 20. Review.

PMID:
25151336

Supplemental Content

Loading ...
Support Center